TMAC Affimer Drug Conjugates

A novel and proprietary class of immuno-oncology active, dual mode of action drug conjugates
 
Despite great progress and excitement surrounding immune-checkpoint targeting therapies, the fact remains that overall response rates across the patient population are low.
 
What approaches can be used to improve the response rate?
 
  • Hitting more than one immune-checkpoint at once through combination therapies, bispecific and trispecific molecules.
  • Combining immune-checkpoint therapies with chemotherapy, viral vaccines, radiotherapy, and others
  • Targeting chemotherapy using drug conjugates
  • Harnessing the power of agonists
 
Avacta is actively addressing the opportunities for Affimers to create novel, safe and effective multispecific immune check point inhibitors and drug conjugates.
 
Download our presentation, which provides an introduction to drug conjugates and to Avacta’s proprietary TMAC (Tissue Microenvironment-Activated Conjugates) platform, a novel and proprietary class of immuno-oncology active, dual mode of action drug conjugates. 

 

Therapeutics Key Benefits

Affimer biotherapeutics have a number of essential advantages over other technologies.

Therapeutic Applications

Affimer biotherapeutics an be developed for a range of applications

Pipeline

Avacta has a pre-clinical stage biopharmaceutical pipeline of Affimer therapeutic candidates for in-house and partnering programmes.